Competition and Consumer Act 2010

IVF 'success rate' claims under the microscope

Several major IVF clinics have made changes to claims published on their websites about success rates following an Australian Competition and Consumer investigation into potentially false or misleading representations. 

“The ACCC reviewed website content from all major Australian IVF clinics and found that some made success-rate comparisons without adequate disclosure about, or qualification of, the nature of the data or graphics used to make the claim,” ACCC Commissioner Sarah Court said. 

Businesses remove unfair contract terms before new law

The Australian Competition and Consumer Commission’s new report into potentially unfair contract terms details its review of 46 contracts across seven industries, which resulted in a range of businesses making changes to their small business standard form contracts.

The ACCC will begin enforcing the new law this week [Nov 12], when consumer protections against unfair contract terms are extended to include up to 2 million Australian small businesses.

ACCC takes contempt action against Dhruv Chopra

The Australian Competition and Consumer Commission has commenced proceedings in the Federal Court against Mr Dhruv Chopra alleging contempt of court.

The ACCC alleges that Mr Chopra has breached orders made by Justice Middleton on 11 May 2015, in earlier proceedings brought by the ACCC. In those proceedings the Federal Court found that Mr Chopra, the sole operator of the online electronics store Electronic Bazaar, made false or misleading representations about the availability of refunds and the extent of Electronic Bazaar’s liability for faulty goods.

ACCC reports on changes to private health insurance policies

The Australian Competition and Consumer Commission has released its annual report on the private health insurance industry, highlighting concerns about how some insurers notify consumers of reductions in their insurance coverage and benefits.

“With over 13 million people in Australia holding some form of private health insurance, the ACCC’s report reveals the challenges in finding out about, understanding and responding to insurer initiated changes to coverage and benefits,” ACCC Deputy Chair Delia Rickard said.

Platform Operators in the Sharing Economy

A guide for complying with the competition and consumer law in Australia.

ACCC Chairman discusses the increasing concentration in Australia’s economy

Correction: a previous version of this media release read: '...the revenue of Australia’s largest 100 listed companies increased from 15% of GDP in 1993 to 47% of GDP in 2015.'

This has been updated to '...the revenue of Australia’s largest 100 listed companies increased from 27% of GDP in 1993 to 47% of GDP in 2015.'

Figure 1 below has been corrected. Figure 3 has also been corrected in the speech link below.

ACCC steers toward effective port regulation

At the Ports Australia Conference in Melbourne, Australian Competition and Consumer Commission Chairman Rod Sims spoke about ensuring proper regulation of privatised port assets and noted some positive outcomes in the ACCC’s engagement with governments.

Mr Sims said the current preference of governments to implement price monitoring regimes fails to ensure there is an effective constraint on monopoly pricing at Australian ports.

ACCC releases issues paper for new car retailing industry market study

The Australian Competition and Consumer Commission has today released an issues paper for the new car retailing industry market study announced in June this year, providing detailed information on the scope of the study and how interested parties can participate.

“A new car is one of the most significant purchases that a consumer will make and issues with these purchases can have a significant financial consequence,” ACCC Chairman Rod Sims said.

ACCC finalises investigation into GlaxoSmithKline’s pricing claims

The Australian Competition and Consumer Commission has concluded its investigation into whether GlaxoSmithKline (GSK) made misleading statements about a price increase of its Panadol Osteo products.

The ACCC investigated concerns that GSK had made statements that linked a price increase of Panadol Osteo to the delisting of the product from the Pharmaceutical Benefits Scheme.